JP2019535240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535240A5 JP2019535240A5 JP2019520527A JP2019520527A JP2019535240A5 JP 2019535240 A5 JP2019535240 A5 JP 2019535240A5 JP 2019520527 A JP2019520527 A JP 2019520527A JP 2019520527 A JP2019520527 A JP 2019520527A JP 2019535240 A5 JP2019535240 A5 JP 2019535240A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- polypeptide
- cell
- cells
- onui
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 88
- 210000004027 cell Anatomy 0.000 claims description 85
- 229920001184 polypeptide Polymers 0.000 claims description 77
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 77
- 239000012634 fragment Substances 0.000 claims description 33
- 102000040430 polynucleotide Human genes 0.000 claims description 30
- 108091033319 polynucleotide Proteins 0.000 claims description 30
- 239000002157 polynucleotide Substances 0.000 claims description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 102000006306 Antigen Receptors Human genes 0.000 claims description 14
- 108010083359 Antigen Receptors Proteins 0.000 claims description 14
- 230000004568 DNA-binding Effects 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- 102220605235 Heparan sulfate N-sulfotransferase 4_S36K_mutation Human genes 0.000 claims description 6
- 102220513921 Histamine H1 receptor_S35R_mutation Human genes 0.000 claims description 6
- 102220630183 Immunoglobulin alpha-2 heavy chain_A76S_mutation Human genes 0.000 claims description 6
- 102220553625 Lens fiber major intrinsic protein_E42S_mutation Human genes 0.000 claims description 6
- 102220635881 Prokineticin receptor 1_S40G_mutation Human genes 0.000 claims description 6
- 102220559237 Voltage-dependent L-type calcium channel subunit alpha-1C_N32R_mutation Human genes 0.000 claims description 6
- 102220352322 c.232A>C Human genes 0.000 claims description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 6
- 102220332529 rs1029534680 Human genes 0.000 claims description 6
- 102220307145 rs1556367745 Human genes 0.000 claims description 6
- 102220028523 rs199469672 Human genes 0.000 claims description 6
- 102220011641 rs201315884 Human genes 0.000 claims description 6
- 102220012151 rs201449986 Human genes 0.000 claims description 6
- 102220097768 rs876661385 Human genes 0.000 claims description 6
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 108060002716 Exonuclease Proteins 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 102000013165 exonuclease Human genes 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 4
- 102000004533 Endonucleases Human genes 0.000 claims description 3
- 108010042407 Endonucleases Proteins 0.000 claims description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 3
- 239000012642 immune effector Substances 0.000 claims description 3
- 229940121354 immunomodulator Drugs 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 claims description 2
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 48
- 230000001506 immunosuppresive effect Effects 0.000 description 27
- 239000003623 enhancer Substances 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000005782 double-strand break Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- -1 CD8α Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 4
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 4
- 102100037935 Polyubiquitin-C Human genes 0.000 description 4
- 102000009572 RNA Polymerase II Human genes 0.000 description 4
- 108010009460 RNA Polymerase II Proteins 0.000 description 4
- 108010056354 Ubiquitin C Proteins 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 2
- 206010066476 Haematological malignancy Diseases 0.000 description 2
- 108010031676 Kynureninase Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 102000005447 kynureninase Human genes 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101100162704 Emericella nidulans I-AniI gene Proteins 0.000 description 1
- 102000004150 Flap endonucleases Human genes 0.000 description 1
- 108090000652 Flap endonucleases Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022066868A JP2022103174A (ja) | 2016-10-17 | 2022-04-14 | ＴＧＦβＲ２エンドヌクレアーゼバリアント、組成物、および使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409163P | 2016-10-17 | 2016-10-17 | |
| US62/409,163 | 2016-10-17 | ||
| US201662414260P | 2016-10-28 | 2016-10-28 | |
| US62/414,260 | 2016-10-28 | ||
| PCT/US2017/057014 WO2018075541A1 (en) | 2016-10-17 | 2017-10-17 | TGFβR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022066868A Division JP2022103174A (ja) | 2016-10-17 | 2022-04-14 | ＴＧＦβＲ２エンドヌクレアーゼバリアント、組成物、および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535240A JP2019535240A (ja) | 2019-12-12 |
| JP2019535240A5 true JP2019535240A5 (enExample) | 2020-11-19 |
| JP7060591B2 JP7060591B2 (ja) | 2022-04-26 |
Family
ID=62018976
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520527A Active JP7060591B2 (ja) | 2016-10-17 | 2017-10-17 | ＴＧＦβＲ２エンドヌクレアーゼバリアント、組成物、および使用方法 |
| JP2022066868A Withdrawn JP2022103174A (ja) | 2016-10-17 | 2022-04-14 | ＴＧＦβＲ２エンドヌクレアーゼバリアント、組成物、および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022066868A Withdrawn JP2022103174A (ja) | 2016-10-17 | 2022-04-14 | ＴＧＦβＲ２エンドヌクレアーゼバリアント、組成物、および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11530395B2 (enExample) |
| EP (1) | EP3526334A4 (enExample) |
| JP (2) | JP7060591B2 (enExample) |
| CN (1) | CN110050066A (enExample) |
| AU (1) | AU2017346683B2 (enExample) |
| CA (1) | CA3040157A1 (enExample) |
| MA (1) | MA46543A (enExample) |
| WO (1) | WO2018075541A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| IL265045B2 (en) | 2016-09-08 | 2023-09-01 | Bluebird Bio Inc | Variants of endonuclease pd-1, compositions and methods of use |
| BR112020018658A2 (pt) | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | Composições de regulação gênica e métodos para imu-noterapia aprimorada |
| CN110904045A (zh) * | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| EP3893886A4 (en) * | 2018-12-10 | 2022-09-28 | 2seventy bio, Inc. | Pdcd-1 homing endonuclease variants |
| KR20210102925A (ko) | 2018-12-10 | 2021-08-20 | 블루버드 바이오, 인코포레이티드. | 호밍 엔도뉴클레아제 변이체 |
| KR20220016474A (ko) | 2019-05-01 | 2022-02-09 | 주노 쎄러퓨티크스 인코퍼레이티드 | 변형된 ｃｄ247 유전자 자리로부터 키메라 수용체를 발현하는 세포, 관련 폴리뉴클레오타이드 및 방법 |
| BR112021021075A2 (pt) * | 2019-05-01 | 2021-12-14 | Editas Medicine Inc | Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos |
| WO2023081900A1 (en) * | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| AU8605598A (en) | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| ES2256265T3 (es) | 2000-06-01 | 2006-07-16 | University Of North Carolina At Chapel Hill | Vectores de parvovirus duplicados. |
| FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| CA2591544A1 (en) | 2004-12-15 | 2006-06-22 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| EP2126066B1 (en) * | 2007-02-19 | 2013-05-01 | Cellectis | Laglidadg homing endonuclease variants having novel substrate specificity and use thereof |
| EP2660317B1 (en) | 2007-10-31 | 2016-04-06 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| ES2634118T3 (es) | 2009-02-11 | 2017-09-26 | The University Of North Carolina At Chapel Hill | Vectores de virus modificados y métodos para fabricar y utilizar los mismos |
| US20110294217A1 (en) | 2009-02-12 | 2011-12-01 | Fred Hutchinson Cancer Research Center | Dna nicking enzyme from a homing endonuclease that stimulates site-specific gene conversion |
| ES2683695T3 (es) | 2010-01-12 | 2018-09-27 | The University Of North Carolina At Chapel Hill | Repeticiones terminales invertidas restrictivas para vectores virales |
| CA2788682C (en) | 2010-02-05 | 2019-03-05 | The University Of North Carolina At Chapel Hill | Compositions and methods for enhanced parvovirus transduction |
| WO2011156430A2 (en) * | 2010-06-07 | 2011-12-15 | Fred Hutchinson Cancer Research Center | Generation and expression of engineered i-onui endonuclease and its homologues and uses thereof |
| EP4062927A1 (en) | 2011-02-28 | 2022-09-28 | Seattle Children's Research Institute | Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption |
| US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
| WO2014172584A1 (en) | 2013-04-17 | 2014-10-23 | Baylor College Of Medicine | IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER |
| ES2883131T3 (es) * | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| EP3004149B1 (en) * | 2013-05-31 | 2018-12-19 | Cellectis S.A. | A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof |
| AU2014273091B2 (en) * | 2013-05-31 | 2019-12-12 | Cellectis | A LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof |
| EP3925618A1 (en) | 2013-07-29 | 2021-12-22 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| CN109689865A (zh) | 2016-07-25 | 2019-04-26 | 蓝鸟生物公司 | Bcl11a归巢核酸内切酶变体、组合物和使用方法 |
| CA3034094A1 (en) | 2016-08-16 | 2018-02-22 | Bluebird Bio, Inc. | Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use |
| US20190262398A1 (en) | 2016-08-23 | 2019-08-29 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
| IL265045B2 (en) | 2016-09-08 | 2023-09-01 | Bluebird Bio Inc | Variants of endonuclease pd-1, compositions and methods of use |
| KR20190065382A (ko) | 2016-10-11 | 2019-06-11 | 블루버드 바이오, 인코포레이티드. | TCRα 호밍 엔도뉴클레아제 변이체 |
-
2017
- 2017-10-17 AU AU2017346683A patent/AU2017346683B2/en active Active
- 2017-10-17 WO PCT/US2017/057014 patent/WO2018075541A1/en not_active Ceased
- 2017-10-17 JP JP2019520527A patent/JP7060591B2/ja active Active
- 2017-10-17 CN CN201780076229.5A patent/CN110050066A/zh active Pending
- 2017-10-17 EP EP17861537.3A patent/EP3526334A4/en active Pending
- 2017-10-17 US US16/341,228 patent/US11530395B2/en active Active
- 2017-10-17 MA MA046543A patent/MA46543A/fr unknown
- 2017-10-17 CA CA3040157A patent/CA3040157A1/en active Pending
-
2022
- 2022-04-14 JP JP2022066868A patent/JP2022103174A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535240A5 (enExample) | ||
| JP2019526268A5 (enExample) | ||
| JP2020521456A5 (enExample) | ||
| JP2020507342A5 (enExample) | ||
| JP7553440B2 (ja) | 抗ｃｄ３３免疫細胞癌療法 | |
| US20240108705A1 (en) | Il-36 secreting immunoresponsive cells and uses thereof | |
| CA3032838A1 (en) | Compositions and methods for immunotherapy | |
| CN111263808B (zh) | 一种靶向HPK1的gRNA和一种编辑HPK1基因的方法 | |
| JP2018510881A (ja) | がん治療のための遺伝子改変ｎｋ−９２細胞およびモノクローナル抗体 | |
| KR20210141573A (ko) | 항-bcma 키메라 항원 수용체 | |
| JP7431735B2 (ja) | Ｄａｒｉｃインターロイキン受容体 | |
| CN114206928B (zh) | Cd33靶向免疫疗法 | |
| CN113412276A (zh) | 二聚化剂调节的免疫受体复合物 | |
| KR20160105882A (ko) | 신규한 합성 생물학에 기반한 adcc 기술 | |
| CN114502586B (zh) | Cll-1靶向免疫疗法 | |
| Stärck et al. | Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell–derived T cells | |
| WO2019192526A1 (zh) | 嵌合抗原受体和其治疗癌症的方法 | |
| KR20200108285A (ko) | Nkg2d daric 수용체 | |
| EP4370699A2 (en) | Polycistronic vectors for cell-based therapies | |
| CA3194577A1 (en) | Methods for triggering safety killing mechanisms using a cd47-sirp.alpha. blockade agent | |
| WO2021050862A1 (en) | Antigen recognizing receptors targeting cd371 and uses thereof | |
| CN114402079A (zh) | Cd123靶向免疫疗法 | |
| CN116802203A (zh) | 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法 | |
| RU2019110065A (ru) | Варианты, композиции и методы применения хоминг-эндонуклеазы pd-1 | |
| RU2019141853A (ru) | Варианты, композиции и способы применения эндонуклеазы cblb |